Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia

Journal of Opioid Management

Volumn 7, Issue 5, 2011, Pages 337-344

  Nasr, Dalia Abdelhamid Mohamed ^a   Omran, Hani Abdelfattah Said Ahmed ^a   Hakim, Sameh Michel ^a   Mansour, Waleed Ahmed Abdelrahman ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Addiction; Dexmedetomidine; Opiate detoxification; Ultra rapid detoxification

Indexed keywords

DEXMEDETOMIDINE; DIAMORPHINE; MORPHINE; NALTREXONE; OPIATE; PROPOFOL;

ABDOMINAL CRAMP; ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DETOXIFICATION; FOLLOW UP; GENERAL ANESTHESIA; HEART RATE; HEMODYNAMICS; HOT FLUSH; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MUSCLE TWITCH; MYDRIASIS; NAUSEA; OBJECTIVE OPIATE WITHDRAWAL SCALE; OPIATE ADDICTION; PATIENT SATISFACTION; PSYCHOLOGICAL RATING SCALE; REFLEX; RHINORRHEA; SUBJECTIVE OPIATE WITHDRAWAL SCALE; SYSTOLIC BLOOD PRESSURE; TREMOR; VOMITING; WITHDRAWAL SYNDROME; YAWNING;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; ANESTHESIA, GENERAL; ANESTHETICS, INTRAVENOUS; CHI-SQUARE DISTRIBUTION; DEXMEDETOMIDINE; DRUG ADMINISTRATION SCHEDULE; EGYPT; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PATIENT SATISFACTION; PROPOFOL; QUESTIONNAIRES; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 81855180401     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0074     Document Type: Article

References (24)

1. Kaye A, Gevirtz C, Bosscher H, et al.: Ultrarapid opiate detoxification: A review. Can J Anaesth. 2003; 50: 663-671. (Pubitemid 37321971)
2. BlueCross and BlueShield Association: Rapid opioid detoxification, Corporate Medical Policy. Reference Manual, Policy No. 3.01.02. Medical Policy, 2009: 1-3.
3. Krantz MJ, Mehler PS: Treating opioid dependence. Growing implications for primary care. Arch Intern Med. 2004; 164: 277-288. (Pubitemid 38180528)
4. Virtanen R, Savola JM, Saano V, et al.: Characterization of the selectivity, specificity and potency of medetomidine as an α2adrenoceptor agonist. Eur J Pharmacol. 1988; 150: 9-14.
5. Arain SR, Ebert TJ: The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002; 95: 461-466. (Pubitemid 34793121)
6. Handelsman L, Cochrane KJ, Aronson MJ, et al.: Two new rating scales for opiate withdrawal. Am J Alcohol Abuse. 1987; 13: 293-308. (Pubitemid 17143298)
7. Maze M, Virtanen R, Daunt D, et al.: Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: In vivo and in vitro studies. Anesth Analg. 1991; 73: 204-208.
8. Aley KO, Levine JD: Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. J Neurosci. 1997; 17: 3907-3912. (Pubitemid 27200612)
9. Ashton H: Benzodiazepine withdrawal: Outcome in 50 patients. Br J Addict. 1987; 82: 665-671.
10. Milne B: Alpha-2 agonists and anaesthesia. Can J Anaesth. 1991; 38: 809-813.
11. Leslie J: Advances in anesthetic pharmacology. Audio-Dig Anesthesiol. 2007; 49(3).
12. Collins E, Kleber HD, Whittington RA, et al.: Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction. JAMA. 2005; 294: 903-913. (Pubitemid 41215459)
13. De Jong CA, Laheij JF, Krabbe PF: General anesthesia does not improve outcome in opioid antagonist detoxification treatment: A randomized controlled trial. Addiction. 2005; 100: 206-215. (Pubitemid 40255378)
14. Hensel M, Kox WJ: Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: A prospective study in methadone, heroin, codeine and morphine addicts. Acta Anaesthesiol Scand. 2000; 44: 326-333. (Pubitemid 30131371)
15. Gold CG, Cullen DJ, Gonzales S, et al.: Rapid opioid detoxification during general anesthesia: A review of 20 patients. Anesthesiology. 1999; 91: 1639-1647.
16. Finkel JC, El Refai A: The use of dexmedetomidine to facilitate opioid and benzodiazepine detoxification in an infant. Anesth Analg. 2004; 98: 1658-1659. (Pubitemid 38668910)
17. Cucchia AT, Monnat M, Spagnoli J, et al.: Ultra-rapid opiate detoxification using deep sedation with oral midazolam: Short and long-term results. Drug Alcohol Depend. 1998; 52: 243-250. (Pubitemid 28529582)
18. McDonald T, Berkowitz R, Hoffman WE: Plasma naltrexone during opioid detoxification. J Addict Dis. 2000; 19: 59-64.
19. Legarda JJ, Gossop M: A 24-h inpatient detoxification treatment for heroin addicts: A preliminary investigation. Drug Alcohol Depend. 1994; 35: 91-93. (Pubitemid 24154028)
20. Poshychinda V: Thailand: Treatment at the Tam Kraborg Temple. In Edwards G, Arif A (eds.): Drug Problems in the Sociocultural Context: A Basis for Policies and Program Planning. Geneva: World Health Organization, 1980: 121-125.
21. Maze M, Segal IS, Bloor BC: Clonidine and other α-2 adrenergic agonists: Strategies for the rational use of these novel anesthetic agents. J Clin Anesth. 1988; 1: 146-157.
22. Maccioli GA: Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003; 98: 575-577.
23. Staedt J, Wassmuth F, Stoppe G, et al.: Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Eur Arch Psychiatry Clin Neurosci. 1996; 246: 305-309. (Pubitemid 26340818)
24. Shukry M, Cain J: Dexmedetomidine prevents and treats agitation, delirium, and withdrawal. Int Trauma Care (ITACCS). 2007; 17(1): 24-26.